ArticleESMO open2024

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

S Michels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.